Opdivo® (nivolumab), Cabometyx® (cabozantinib) – Expanded indication
January 21, 2021 - Bristol Myers Squibb and Exelixis announced the FDA approval of Opdivo (nivolumab) plus Cabometyx (cabozantinib), for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
Download PDF
